Your browser doesn't support javascript.
loading
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants.
Messaoudene, M; Mourikis, T P; Michels, J; Fu, Y; Bonvalet, M; Lacroix-Trikki, M; Routy, B; Fluckiger, A; Rusakiewicz, S; Roberti, M P; Cotteret, S; Flament, C; Poirier-Colame, V; Jacquelot, N; Ghiringhelli, F; Caignard, A; Eggermont, A M M; Kroemer, G; Marabelle, A; Arnedos, M; Vicier, C; Dogan, S; Jaulin, F; Sammut, S-J; Cope, W; Caldas, C; Delaloge, S; McGranahan, N; André, F; Zitvogel, L.
  • Messaoudene M; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France.
  • Mourikis TP; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Michels J; Gustave Roussy Cancer Campus (GRCC), Villejuif; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif.
  • Fu Y; Gustave Roussy Cancer Campus (GRCC), Villejuif.
  • Bonvalet M; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France.
  • Lacroix-Trikki M; Gustave Roussy Cancer Campus (GRCC), Villejuif; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
  • Routy B; Gustave Roussy Cancer Campus (GRCC), Villejuif; Universitéde Montréal Hospital Research Centre (CRCHUM), Onco-Hematology Department, Montreal University Hospital Center (CHUM), Montréal, Québec, Canada.
  • Fluckiger A; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
  • Rusakiewicz S; Center of Experimental Therapeutics (CET), Department of Oncology, Lausanne University Hospital, CHUV, Lausanne, Switzerland.
  • Roberti MP; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
  • Cotteret S; Gustave Roussy Cancer Campus (GRCC), Villejuif.
  • Flament C; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
  • Poirier-Colame V; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
  • Jacquelot N; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif.
  • Ghiringhelli F; Georges-François Leclerc center, Medical Oncology, Dijon.
  • Caignard A; INSERM U1160, University Institute for Haematology, Saint Louis hospital, Paris.
  • Eggermont AMM; Gustave Roussy Cancer Campus (GRCC), Villejuif.
  • Kroemer G; Gustave Roussy Cancer Campus (GRCC), Villejuif; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Cordeliers Research Center, INSERM, U1138, Université Paris Descartes, Sorbonne Paris
  • Marabelle A; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Gustave Roussy Cancer Campus (GRCC), Drug Development Department (DITEP)
  • Arnedos M; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif.
  • Vicier C; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France.
  • Dogan S; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France.
  • Jaulin F; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France.
  • Sammut SJ; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge.
  • Cope W; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge; Cancer Research UK Cancer Centre and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Caldas C; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge.
  • Delaloge S; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif.
  • McGranahan N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • André F; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France.
  • Zitvogel L; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428
Ann Oncol ; 30(6): 934-944, 2019 06 01.
Article en En | MEDLINE | ID: mdl-30924846
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antígenos de Histocompatibilidad Clase I / Protocolos de Quimioterapia Combinada Antineoplásica / Linfocitos Infiltrantes de Tumor / Anticuerpos Biespecíficos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antígenos de Histocompatibilidad Clase I / Protocolos de Quimioterapia Combinada Antineoplásica / Linfocitos Infiltrantes de Tumor / Anticuerpos Biespecíficos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2019 Tipo del documento: Article